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Cancer patient survival in Sweden is generally increasing, and Sweden compares well in an 
international perspective. Despite these achievements, there are nevertheless socio-economic 
and regional differences in survival that need to be addressed to meet the intensions of the 
Swedish Health and Medical Service Act. The Act emphasises good health and access to care 
for the entire population where priority shall be given to those in the greatest need of care. 
The new organisational structure for oncological care that is now being implemented, with 
Regional Cancer Centres as central nodes in a network in their respective health care region, 
will hopefully be able to address these inequalities and take the past achievements in cancer 
patient survival even further. 
 The quality and completeness of the Swedish Cancer Register is high. There are neverthe-
less areas regarding procedures for reporting incident cases to the regional registries and reg-
istration that need to be reviewed as a certain degree of under-reporting does exist. The under-
reporting appears to be systematic rather than random as it is site-specific, increases with age, 
and non-reported tumours are often without histopathological verification. For most uses in 
epidemiology, the degree of under-reporting will be without significant consequences, but to a 
varying degree, it will have implications for specific research questions. The accuracy of the 
cancer register should be monitored on a continuous basis rather than in the ad-hoc fashion 
that has been done so far. This is also the method recommended by the International Agency 
for Research on Cancer and in guidelines from the Council for Official Statistics at Statistics 
Sweden. 
 Two studies in this thesis evaluate period-based and cohort-based analyses ability to predict 
long-term survival for recently diagnosed cancer patients. Both studies show that period 
analysis gives better prediction of the future true survival, particularly when not all of the 
available information is used for the cohort analysis. The first of these two studies was the 
first systematic evaluation of period analysis that was independent of the researchers who 
proposed the method. Previous evaluations had mainly been performed using data from the 
Finnish Cancer Registry. This study had a significant role in demonstrating the utility of pe-
riod analysis, which has since become an established method in population-based survival 
analysis. The second study is the first prospective evaluation of the ability of period analysis 
to predict future survival. 
 Relative survival is defined as the observed survival of the cancer patients divided by the 
expected survival of a comparable group from the general population, free from the specific 
cancer under study. However, as expected survival is usually calculated from general popula-
tion life tables these estimates are biased. This bias is generally ignored since mortality 
among individuals with a specific cancer is regarded as a small negligible part of the total 
mortality of the general population. To estimate the size of this bias the Swedish computer-
ised population registers were used to calculate expected survival both including and exclud-
ing individuals with cancer. A simple method to correct for this bias using cause of death sta-
tistics was also evaluated. The results show that the bias is often sufficiently small to be ig-
nored for most applications, especially for cancers with high or low mortality and for younger 
age groups. However, for older age groups and for common cancers the bias can be greater 
than one percent unit, and even larger for all cancer sites combined. The proposed method to 
correct for this bias seems to work well, and it may often be sufficient to use cause of death 
statistics for one recent year to gain a satisfactory correction to the bias. 
 
ISBN 978-91-7457-530-9 
